EU migraine drug approval triggers multimillion-dollar bill for Lundbeck

When Lundbeck’s migraine treatment Vyepti was approved by the EU earlier this year, it passed a milestone – for Lundbeck itself, but also for investors in the drug’s original developer, who were now owed a total of USD 230m.

Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix

More than two years after Lundbeck bought migraine drug Vyepti alongside the company behind it, Alder Biopharmaceuticals, which was publicly listed in the US before the acquisition, former investors can look forward to receiving the last bit of money they were promised.

In Lundbeck’s first quarterly report for 2022, which was released on Wednesday, the firm confirms that is has paid out around USD 230m related to Alder’s acquisition during the first quarter.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs